

# Contents

<b>Foreword</b> . . . . .	xiii
Julia COOPER	
<b>Chapter 1. Telomeres: All's Well That Ends Well</b> . . . . .	1
Patrizia ALBERTI	
1.1. Introduction. . . . .	1
1.2. The beginning of the end. . . . .	2
1.2.1. Chemists and biophysicists at work: G-quartets and G-quadruplexes disclose themselves . . . . .	2
1.2.2. Biologists at work: telomeres disclose themselves . . . . .	5
1.2.3. When and where G-quadruplexes and telomeres met . . . . .	9
1.3. Telomeric architectures: from ciliates to other eukaryotes . . . . .	10
1.3.1. Telomeric DNA and telomeric proteins . . . . .	10
1.3.2. Telomeric structures . . . . .	15
1.4. G-quadruplexes at telomeres. . . . .	18
1.4.1. Secondary structures formed by repeats of telomeric motifs. . . . .	18
1.4.2. G4s at telomeres: friendly or unfriendly structures? . . . . .	21
1.5. References . . . . .	26
<b>Chapter 2. Methods to Measure Telomere Lengths</b> . . . . .	39
Lauréline ROGER	
2.1. Why does telomere length matter? . . . . .	39
2.2. Methods for measuring telomere length . . . . .	41

---

2.2.1. Terminal restriction fragment analysis (TRF) . . . . .	41
2.2.2. Single telomere length analysis . . . . .	44
2.2.3. Telomere shortest length assay . . . . .	46
2.2.4. Quantitative-polymerase chain reaction. . . . .	48
2.2.5. Quantitative-fluorescence in situ hybridization . . . . .	50
2.2.6. Flow-fluorescence in situ hybridization . . . . .	52
2.3. References . . . . .	53
<b>Chapter 3. The Shelterin Complex.</b> . . . . .	57
Claire GHILAIN, Eric GILSON and Marie-Josèphe GIRAUD-PANIS	
3.1. TRF1 and TRF2, structurally alike but... . . . . .	59
3.1.1. Domains organization . . . . .	59
3.1.2. Biological roles . . . . .	64
3.2. RAP1 . . . . .	75
3.3. TIN2 . . . . .	79
3.4. TPP1-POT1. . . . .	82
3.5. Quaternary structure of the shelterin . . . . .	86
3.6. Concluding remarks. . . . .	86
3.7. References . . . . .	87
<b>Chapter 4. Mammalian Telomere Organization and Dynamics in the Nuclear Volume</b> . . . . .	105
Sonia STINUS and Laure CRABBE	
4.1. Introduction. . . . .	105
4.2. Nuclear envelope and lamins: orchestrators of cell and genome architecture . . . . .	106
4.2.1. The nuclear envelope landmarks . . . . .	106
4.2.2. The nuclear envelope as a scaffold to organize nuclear architecture . . . . .	107
4.2.3. Nuclear envelope disassembly during mitosis . . . . .	108
4.3. Interplay between telomeres and nuclear structures . . . . .	108
4.4. Telomere tethering to the NE to promote meiotic pairing . . . . .	109
4.5. Telomere organization and dynamics in the nucleus. . . . .	110
4.6. Interaction between telomere chromatin and lamins during post-mitotic nuclear assembly . . . . .	111
4.7. Interaction between telomere chromatin and lamins for telomere maintenance . . . . .	112
4.8. Conclusion . . . . .	113
4.9. References . . . . .	114

<b>Chapter 5. <i>Saccharomyces cerevisiae</i>, a Model at the Forefront of Telomere Biology</b> . . . . .	119
Aurélia BARASCU and Maria Teresa TEIXEIRA	
5.1. Introduction. . . . .	119
5.2. Telomere characterization: various experimental organisms for first historical experiments . . . . .	121
5.3. Protection and proliferation: the telomere dilemma . . . . .	122
5.3.1. Telomeric sequences: pattern conservation and length variations . . . . .	122
5.3.2. Telomeric proteins . . . . .	125
5.3.3. TERRA or telomere transcription . . . . .	128
5.4. Telomere maintenance . . . . .	129
5.4.1. The difficulties of moving replication fork through telomeres . . . . .	129
5.4.2. The end replication problem . . . . .	129
5.4.3. Telomerase: a solution to the problem of telomere shortening . . . . .	132
5.5. Telomeres: one size for one identity . . . . .	134
5.6. Telomeres, replicative senescence, aging and genomic instability . . . . .	136
5.6.1. Aging and replicative senescence . . . . .	136
5.6.2. Heterogeneity of senescence at the single cell level. . . . .	138
5.7. Senescence escape phenomena and genomic instability . . . . .	140
5.8. Conclusion . . . . .	142
5.9. References . . . . .	142
<b>Chapter 6. Dealing with Replication Stress at Telomeres</b> . . . . .	157
Stéphane COULON	
6.1. Introduction. . . . .	157
6.1.1. Telomere, telomerase and shelterin . . . . .	157
6.1.2. Aging, cancer and telomere syndromes . . . . .	159
6.1.3. The telomere replication problem . . . . .	160
6.2. Removal of the DNA structures that impede RF progression . . . . .	162
6.2.1. G-quadruplex dissolution by helicases . . . . .	162
6.2.2. G-quadruplex dissolution by single-strand binding proteins. . . . .	166
6.2.3. T-loop dissolution. . . . .	167
6.2.4. RNA:DNA hybrid removal . . . . .	168
6.2.5. Topological constraints . . . . .	170
6.3. Accessory factors that contribute to telomere replication I . . . . .	171
6.3.1. The CST complex. . . . .	171
6.3.2. The MRN complex and CtIP . . . . .	173
6.3.3. SLX4 . . . . .	174

---

6.3.4. Timeless and AKTIP . . . . .	175
6.3.5. RECQL helicases and SMARCAL1 translocase . . . . .	175
6.4. Concluding remarks . . . . .	176
6.5. References . . . . .	177
<b>Chapter 7. A Brief History of Telomerase: Exceptional Women in Command</b> . . . . .	193
Vincent GÉLI	
7.1. Acknowledgments . . . . .	199
7.2. References . . . . .	199
<b>Chapter 8. Telomerase: Structure and Mechanism</b> . . . . .	205
Carole SAINTOMÉ	
8.1. Introduction . . . . .	205
8.2. Roles . . . . .	206
8.3. Structures . . . . .	207
8.3.1. The catalytic core . . . . .	207
8.3.2. The holoenzyme . . . . .	210
8.4. Biogenesis . . . . .	212
8.5. Mechanism . . . . .	214
8.6. Regulation . . . . .	215
8.7. Disease and therapy . . . . .	216
8.8. Conclusion . . . . .	216
8.9. References . . . . .	217
<b>Chapter 9. Alternative Lengthening of Telomeres</b> . . . . .	223
Mathilde GAUCHIER	
9.1. ALT cell markers . . . . .	224
9.1.1. ALT telomeres are associated with PML bodies: APBs . . . . .	225
9.1.2. Telomeres of heterogeneous size . . . . .	225
9.1.3. The accumulation of extra-chromosomal circular telomeric DNA . . . . .	226
9.1.4. Variant telomeric DNA repeats . . . . .	226
9.1.5. Sister chromatid exchange at telomeres . . . . .	226
9.1.6. The accumulation of TERRA . . . . .	227
9.1.7. Loss of function of the ATRX signaling pathway . . . . .	227
9.2. ALT mechanisms . . . . .	228

9.3. Replicative stress and DNA repair pathway at ALT telomeres . . . . .	229
9.4. The structure of chromatin at ALT telomeres. . . . .	230
9.5. ALT and cancer . . . . .	232
9.6. The ALT pathway: a non-pathological function? . . . . .	232
9.7. Alternative pathways not involving recombination: evolutionary aspects . . . . .	233
9.8. Appendix: experimental methods that allow the identification of the ALT phenotype in human cancer cells. . . . .	236
9.9. References . . . . .	237
<b>Chapter 10. TERRA, Telomeric Non-coding RNAs . . . . .</b>	<b>245</b>
Anabelle DECOTTIGNIES	
10.1. Introduction . . . . .	245
10.2. The human TERRAs . . . . .	246
10.2.1. The majority of human telomeres are transcribed . . . . .	246
10.2.2. Telomere length influences human TERRAs . . . . .	249
10.2.3. Induction of human TERRA expression by different types of stress: metabolic, oxidative stress, heat shock or DNA damage . . . . .	249
10.2.4. Human TERRAs form RNA:DNA hybrids at telomeres to form R-loops . . . . .	251
10.2.5. Other known functions of human TERRAs . . . . .	252
10.3. The mouse TERRAs. . . . .	255
10.3.1. The majority of murine telomeres are probably not transcribed . . . . .	255
10.3.2. PAR-TERRA: a crucial role in homologous sex chromosome pairing and in the regulation of ATRX target gene expression . . . . .	257
10.3.3. Known or predicted functions of murine TERRAs . . . . .	257
10.4. Conclusion . . . . .	258
10.5. References. . . . .	258
<b>Chapter 11. Telomeres and Cancer . . . . .</b>	<b>263</b>
Arturo LONDOÑO-VALLEJO	
11.1. Introduction . . . . .	263
11.2. Short telomeres and telomere-induced senescence are barriers to oncogenic development. . . . .	264
11.3. Excessive shortening of telomeres promotes CIN in the early stages of cancer transformation. . . . .	267
11.4. The contribution of telomere-driven CIN to tumor progression . . . . .	270

11.5. The senescent microenvironment promotes cancer development . . .	271
11.6. Mechanisms of cell immortalization . . . . .	273
11.7. Therapeutic potential of telomeres and telomerase and prognostic value of telomere-related evaluations . . . . .	277
11.8. Conclusion . . . . .	279
11.9. Acknowledgments . . . . .	279
11.10. References . . . . .	280

## **Chapter 12. Physiopathology of Telomeres . . . . .** 291

Caroline KANNENGIESSER and Patrick REVY

12.1. Introduction . . . . .	291
12.2. Telomere length in blood . . . . .	292
12.2.1. Measurement of telomere length . . . . .	292
12.2.2. Telomere length in patients with telomeropathy . . . . .	294
12.3. Different genes associated with telomere defects . . . . .	295
12.3.1. Telomerase complex . . . . .	296
12.3.2. Shelterin complex . . . . .	297
12.3.3. CST complex (CTC1/STN1/TEN1) . . . . .	297
12.3.4. Telomere stability factor . . . . .	297
12.4. Different diseases associated with telomere defects . . . . .	300
12.4.1. Dyskeratosis congenita (DC) . . . . .	300
12.4.2. Hoyeraal–Hreidarsson (HH) syndrome . . . . .	302
12.4.3. The Revesz syndrome . . . . .	303
12.4.4. Coats plus syndrome . . . . .	303
12.4.5. Bone marrow failure . . . . .	304
12.4.6. Lung disease . . . . .	305
12.4.7. Liver disease . . . . .	306
12.4.8. Other clinical impairments . . . . .	307
12.5. Genetic analysis and counseling . . . . .	308
12.5.1. Genetic analysis of telomeropathies . . . . .	308
12.5.2. Genetics of telomeropathies . . . . .	308
12.5.3. Telomeropathy genetic counseling in practice, management of rare diseases in France . . . . .	309
12.5.4. Epigenetic heritability . . . . .	310
12.6. Treatment of diseases associated with telomere defects . . . . .	310
12.7. Compensatory somatic mutations in the <i>TERT</i> promoter . . . . .	311
12.8. Missing heredity . . . . .	312
12.9. Conclusion . . . . .	313
12.10. References . . . . .	313

---

<b>Chapter 13. Telomeres Targeting Agents</b> . . . . .	329
Sophie BOMBARD, Patrick MAILLIET and Marie-Paule TEULADE-FICHO	
13.1. Introduction . . . . .	329
13.2. Chemistry and <i>in vitro</i> properties of G4 ligands targeting telomeres . . . . .	330
13.2.1. Condensed heteroaromatics: the first generations . . . . .	331
13.2.2. Macrocyclic polyheteroaryles . . . . .	334
13.2.3. Bisquinolinium and bisquinoline compounds with an aromatic dicarboxamide core (triazines, 360A, PhenDC3, PDS) . . . . .	336
13.2.4. Alternative hybrid scaffolds derived from the series above . . . . .	339
13.2.5. Telomeric localization of G4 ligands through imaging . . . . .	340
13.3. Biological properties of G4 ligands targeting telomeres . . . . .	341
13.4. Metal complexes targeting telomeres . . . . .	344
13.5. Compounds targeting the proteins of the human shelterin complex . . . . .	348
13.5.1. Inhibitors of the shelterin proteins binding to DNA . . . . .	349
13.5.2. Inhibitors of protein–protein interactions involving the shelterin proteins . . . . .	351
13.5.3. Chemical modulators of the shelterin proteins . . . . .	352
13.6. Compounds targeting telomerase . . . . .	355
13.6.1. Oligonucleotides as telomerase inhibitors . . . . .	355
13.6.2. Small molecule as inhibitors of telomerase . . . . .	356
13.6.3. Biologics as inhibitors of telomerase . . . . .	357
13.7. General conclusion . . . . .	357
13.8. Acknowledgments . . . . .	358
13.9. References . . . . .	358
<b>List of Authors</b> . . . . .	373
<b>Index</b> . . . . .	377